PMCB — PharmaCyte Biotech, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2021-08-10.
Performance
Technicals
Others in Healthcare
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-01-07 | Silverman Joshua CEO and President | Open-market purchase | 40.0K | 0.83 | 33.2K |
| 2026-01-07 | SCHECHTER JONATHAN Director | Open-market purchase | 20.0K | 0.84 | 16.8K |
| 2026-01-06 | Silverman Joshua CEO and President | Open-market purchase | 30.0K | 0.79 | 23.7K |
| 2026-01-06 | SCHECHTER JONATHAN Director | Open-market purchase | 20.0K | 0.79 | 15.8K |
| 2026-01-05 | Silverman Joshua CEO and President | Open-market purchase | 30.0K | 0.78 | 23.4K |
| 2026-01-05 | SCHECHTER JONATHAN Director | Open-market purchase | 20.0K | 0.78 | 15.6K |
| 2025-12-12 | Silverman Joshua CEO and President | Shares withheld for tax | 258.8K | 1.02 | 263.9K |
| 2025-12-12 | SCHECHTER JONATHAN Director | Shares withheld for tax | 67.5K | 1.02 | 68.8K |
| 2025-12-12 | WEINSTEIN ROBERT Director | Shares withheld for tax | 33.8K | 1.02 | 34.4K |
| 2025-12-12 | WALKER WAYNE REMELL Director | Shares withheld for tax | 16.9K | 1.02 | 17.2K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| CITADEL ADVISORS LLC | 239.2K | 359.5K |
| GEODE CAPITAL MANAGEMENT, LLC | 130.2K | 195.7K |
| RENAISSANCE TECHNOLOGIES LLC | 37.6K | 56.5K |
| XTX Topco Ltd | 34.8K | 52.4K |
| VANGUARD CAPITAL MANAGEMENT LLC | 34.2K | 51.5K |
| NORTHERN TRUST CORP | 23.7K | 35.6K |
| Schonfeld Strategic Advisors LLC | 18.0K | 27.0K |
| VANGUARD FIDUCIARY TRUST CO | 15.6K | 23.5K |
| EQUITEC PROPRIETARY MARKETS, LLC | 14.8K | 22.2K |
| SIMPLEX TRADING, LLC | 13.3K | 19.9K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 10-K | 2026-07-29 | 2026-04-30 | on EDGAR ↗ |
| 4/A | 2026-07-17 | 2026-03-31 | on EDGAR ↗ |
| 4/A | 2026-07-17 | 2026-03-31 | on EDGAR ↗ |
| 4/A | 2026-07-17 | 2026-03-31 | on EDGAR ↗ |
| 4/A | 2026-07-17 | 2026-03-31 | on EDGAR ↗ |
| 4 | 2026-04-02 | 2026-03-31 | on EDGAR ↗ |
| 4 | 2026-04-02 | 2026-03-31 | on EDGAR ↗ |
| 4 | 2026-04-02 | 2026-03-31 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about PMCB
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →